Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Tabacova
Sonia A
SA
National Center for Toxicological Research, US Food and Drug Administration, Rockville, MD, USA. S.Tabacova@nctr.fda.gov
Kimmel
Carole A
CA
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D001262:Atenolol / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000494:pharmacology; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001262:Atenolol